An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Bevacizumab (Primary) ; Eftozanermin-alfa (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 30 Jan 2023 Results assessing Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia published in the Blood
- 25 Apr 2022 Results (n=105) published in the Investigational New Drugs
- 10 Mar 2022 Status changed from active, no longer recruiting to completed.